THE WOODLANDS, Texas, March 16, 2011 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX)today announced it has commenced dosing the 6 mg cohort in the Company’s low dose study of Proellex® following a safety review of data from women that have completed 8 weeks of treatment at a 3 mg dose. No signals of liver toxicity were detected to date in the 3 mg group. Increased levels of drug activity were detected in this second cohort. The Company previously noted that it has observed signals of clinically relevant activity at even the lowest dose, 1 mg.
